Efficacy of the BNT162b2 mRNA Vaccine in Qatar As of March 31, 2021, more than 265,000
people in Qatar had received both doses of the BNT162b2 vaccine. Viral sequencing …

The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna)
vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-…

Objective To describe patterns of HIV infection among stable sexual partnerships across sub-Saharan
Africa (SSA). Methods The authors defined measures of HIV discordancy and …

Background Waning of vaccine protection against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The …

Protection against Omicron by Previous SARS-CoV-2 Infection Using a national Covid-19
database in Qatar, investigators found that previous SARS-CoV-2 infection provided protection …

Background The protection conferred by natural immunity, vaccination, and both against
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the …

Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19)
and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory …

SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted
a matched, test-negative, case-control study to estimate duration of protection of the second …

Background Herpes simplex virus type 1 (HSV-1) epidemiology in Asia was characterized
by assessing seroprevalence levels and extent to which HSV-1 is isolated from clinically …

… Hiam Chemaitelly, Ph.D. … Ayoub HH, Tomy M, Chemaitelly H, et al. Estimating
protection afforded by prior infection in preventing reinfection: applying the test-negative …